Shots:
- Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization rights and will continue to consolidate the sales of Elunate in China while Chi-Med retains all rights to fruquintinib outside of China
- The agreement allows the company to deploy full resources of both companies to maximize the potential of the Elunate in China. From Oct 01, 2020, Chi-Med will be responsible to develop and execute all medical detailing, promotion, and marketing activities for the product in China
- Fruquintinib is a highly selective and potent oral VEGFR 1/2/3 inhibitor, acts by minimizing off-target toxicities, improve tolerability and provide more consistent target coverage
Click here to read full press release/ article | Ref: PRNewswire | Image: StraitTimes
